SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours (GEP NETS)
SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours (GEP NETS)
复制标题
DOI：
10.1007/s12094-011-0695-9
复制
发表时间：
2011-08-01
影响因子：
3.4
通讯作者：
Isla, Dolores
中科院分区：
文献类型：
--
作者：
Garcia-Carbonero, Rocio;Salazar, Ramon;Isla, Dolores
胃肠胰腺神经内分泌肿瘤（GEP NETs）是一种异质性肿瘤家族，其发病率不断上升，临床管理具有挑战性。与其他实体肿瘤不同，它们有能力分泌不同的多肽和神经胺，导致不同的临床综合征。然而，许多在临床上沉默，直到疾病晚期。本指南旨在为GEP NETs的诊断和治疗提供实用建议。最新的组织学和分期分类，以及可用的治疗方法，如手术，局部治疗，肽受体放射性核素治疗（PRRT）和激素或全身治疗，在这篇文章中讨论，包括一些最新的相关成果与新的靶向药物。临床表现（是否有激素综合征）、肿瘤组织学特征（包括增殖指数（Ki-67）和是否存在生长抑素受体）、肿瘤分期、原发肿瘤和远处转移的位置都是合理设计和整合最合适治疗策略的关键问题。
Gastroenteropancreatic neuroendocrine tumours (GEP NETs) represent a heterogenous family of tumours with growing incidence and challenging clinical management. Unlike other solid tumours, they have the ability to secrete different peptides and neuramines that cause distinct clinical syndromes. However, many are clinically silent until advanced disease. This guideline aims to provide practical recommendations for the diagnosis and treatment of GEP NETs. Most recent histological and staging classifications, as well as available therapeutic approaches, such as surgery, locoregional therapy, peptide receptor radionuclide therapy (PRRT) and hormonal or systemic therapy, are discussed in this manuscript, including some recent relevant achievements with novel targeted agents. Clinical presentation (with or without hormonal syndrome), histological tumour features (including proliferation index (Ki-67) and the presence or not of somatostatin receptors), tumour stage, and location of primary tumour and distant metastasis are all key issues that shall be taken into consideration to properly design and integrate the most adequate therapeutic strategy.